Early detection of cancers saves lives, and MiRXES’ miRNA-based blood test for gastric cancer is a world’s first, building on years of development in Singapore, making screening and risk-stratification of patients easier and more accessible. The company has also played a key role in deploying the Fortitude COVID-19 PCR tests globally, and with EDBI Pte Ltd’s partnership, will accelerate the development of important next generation diagnostics technologies from bench to market.
This Series C round was led by CR-CP Life Science Fund, a 50-50 joint venture between China Resources Group and Thailand’s Charoen Pokphand Group. Other investors include global healthcare investment firm Rock Springs Capital and Singapore-based EDBI.
